Naptumomab estafenatox
- Generic Name
- Naptumomab estafenatox
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 676258-98-3
- Unique Ingredient Identifier
- 93T929W6LC
- Background
Naptumomab Estafenatox has been used in trials studying the treatment of Pancreatic Cancer, Renal Cell Carcinoma, and Non-Small-Cell Lung Carcinoma.
- Associated Conditions
- -
- Associated Therapies
- -
Naptumomab Estafenatox in Combination With Pembrolizumab Preceded by Obinutuzumab in Patients With Urothelial Cancers
Phase 1
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2023-06-08
- Last Posted Date
- 2024-04-12
- Lead Sponsor
- Weill Medical College of Cornell University
- Registration Number
- NCT05894447
- Locations
- 🇺🇸
Weill Cornell Medicine/NewYork-Presbyterian Hospital, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath